McDermott and Bull executive Search
 

Other News

Route 92 Medical Announces $100 Million Corporate Debt Facility

Financial by 0 comments

Financing Strengthens Balance Sheet and Supports Continued Product Innovation and Commercial GrowthWEST JORDAN, Utah, Oct. 20, 2026 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced that it has entered into a $100 million senior secured debt facility with Trinity Capital Inc., a leading provider of flexible capital solutions for innovative, growth-stage to lower middle market companies across the United States and Europe. Route 92 Medical has developed an integrated neurovascular platform that combines access, delivery, and control in a cohesive system, enabling clinicians to reach treatment sites reliably and efficiently. Tenzing® delivery catheters are foundational to the Route 92 platform, enabling atraumatic, precise, and controlled navigation through complex neurovascular anatomy. All Route 92 access and aspiration catheters are powered by custom-sized Tenzing delivery catheters and are size-matched to the vessels they access. Route 92 has also developed Monopoint®, the only mono-axial neurovascular platform, featuring a streamlined telescoping design that advances from a single point of control to simplify neurovascular intervention. “Entering into this financing with Trinity Capital is an important step for Route 92 as we execute on our growth strategy,” said Raj Denhoy, Chief Financial Officer of Route 92 Medical. “This facility gives us additional financial flexibility to support the strong demand we are seeing for our products. Trinity’s understanding of the medical technology sector and their confidence in our technology, commercial momentum, and long-term vision make them a valuable partner as we work to transform the treatment of neurovascular disease.” Route 92’s portfolio of advanced neurovascular catheters includes the FreeClimb® 46, 54, 70, and 88 systems, as well as the HiPoint® 70 and 88 systems, which feature Monopoint. HiPoint 88 is the first super-bore aspiration system with FDA clearance for direct aspiration of large vessel occlusions (LVOs) in acute ischemic stroke. The most recent addition, FreeClimb 46 with Tenzing 4, offers a differentiated tool for navigating more distal and smaller anatomies. Route 92’s catheters and systems are covered by a portfolio of more than 200 issued patents in the U.S. and international jurisdictions. About Route 92 Medical, Inc.Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering, innovative product design, and revolutionary procedural change. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. CONTACT: Contacts:

For media:
Gwen Gordon
Gwen@gwengordonpr.com

Continue Reading →
Philips cardiology informatics at TCT

Philips highlights Integrated Diagnostics’ role in the future of cardiovascular informatics following MediReport acquisition

Coronary/Structural Heart by 0 comments

Philips cardiology informatics at TCT

Philips cardiology informatics at TCT

October 20, 2026 Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience.  Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026.   Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care.   Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up.   In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway.  Following the acquisition of MediReport, Philips expects to strengthen its cardiovascular informatics capabilities. MediReport 360 supports structured cardiovascular documentation and real-time reporting at the point of care, with guided workflows before, during and after procedures. It enables health systems to capture clinical information once and reuse it across physician and nursing reports, coding, registries, analytics, charge capture and follow-up. MediReport’s technologies support cloud and on-premises deployment, with vendor-neutral interfaces to imaging systems, hemodynamic systems and hospital IT.    This expected enhancement would build on Philips’ existing cardiology informatics portfolio, including Cardiovascular Workspace for image and information management, with cloud deployment available in North America; Ultrasound Workspace for ultrasound review, analysis and reporting; and interventional solutions supporting cath-lab information management and hemodynamic workflows.   “Clinicians need technology that fits the way they work and gives them more time for patient care”, said Madhuri Sebastian, Business Unit Leader Imaging Informatics at Philips. “The capabilities developed by MediReport complement Philips’ strengths in cardiovascular imaging, hemodynamics and enterprise informatics. Together, they are expected to simplify how information moves across cardiac care, enabling a more connected experience for care teams. This would also support Philips’ longer-term direction towards cloud-ready, AI-enabled cardiovascular and integrated diagnostics workflows.”   Visit Philips at TCT 2026 to explore innovations in imaging, physiology, procedural guidance and cardiovascular informatics that help care teams access meaningful information and simplify reporting and workflows. [1] Philips Future Health Index 2025: Cardiology Snapshot — Building trust in AI for cardiac care.  For further information, please contact: Name Jayme ManiatisPhilips Global External RelationsTel.: +16178948368E-mail: name.here@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Philips cardiology informatics at TCT

Continue Reading →

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

Coronary/Structural Heart Regulatory by 0 comments

MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial’s European footprint. Germany is Europe’s largest and most established transcatheter aortic valve replacement (TAVR) market, with an extensive network of experienced structural heart centers and investigators. Activating sites in this high-volume environment is anticipated to increase access to eligible patients and accelerate enrollment in the PARADIGM Trial.  “Germany’s scale, clinical expertise and established TAVR infrastructure create an important opportunity to advance enrollment and extend PARADIGM’s reach across leading international TAVR markets,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris. The Company continues to execute its global clinical strategy through coordinated site activation and patient enrollment across the United States and Europe. Germany’s inclusion strengthens the trial’s European presence and adds meaningful scale to the PARADIGM Trial. ENDS About the PARADIGM Trial The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enrol approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. For further information, please refer to ClinicalTrials.gov NCT07194265. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements, including statements regarding the expectation that this regulatory clearance enables patient recruitment in Germany. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information: Global Investor Relationsinvestors@anteristech.comDebbie OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200Investor Relations (US)mchatterjee@bplifescience.comMalini Chatterjee, Ph.D.       Blueprint Life Science Group+1 917 330 4269        Website         www.anteristech.comX                 @AnterisTechLinkedIn         https://www.linkedin.com/company/anteristech

Continue Reading →

Remote Heart Monitoring at KFSH Reduces Heart Failure Admissions by 46%

Coronary/Structural Heart by 0 comments

KFSH Virtual Care Remote Patient Follow-Up

A KFSH physician follows up with a patient remotely

RIYADH, Saudi Arabia, Oct. 19, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH) has reduced hospital admissions for decompensated heart failure by 46.4% among patients fitted with an implantable pulmonary artery pressure sensor, according to a center analysis of 130 recipients who completed six months of follow-up, compared with the same patients’ experience before implantation. The CardioMEMS sensor allows KFSH’s Heart Center of Excellence to monitor pulmonary artery pressure remotely and identify early signs of worsening heart failure. Clinical teams can then adjust treatment while the patient remains at home, rather than waiting for symptoms to require an emergency visit or admission. Remote monitoring is part of a wider set of technologies that extend specialist oversight beyond the hospital. The center also uses artificial intelligence to support electrocardiogram analysis and offers leadless pacemakers for selected pediatric and congenital heart disease patients. A round-the-clock virtual cardiac service handles urgent concerns after discharge through defined escalation pathways. For patients whose heart failure advances, KFSH provides a full continuum of specialist care, including ventricular assist devices, extracorporeal membrane oxygenation, and heart transplantation. In 2024, KFSH performed the world’s first fully robotic heart transplant, and in 2025 the world’s first robotic-assisted implantation of a HeartMate 3 heart pump. Fewer admissions mean more time at home for patients and fewer disruptions to their families and work. They also preserve specialist hospital capacity for patients who require inpatient treatment, in a center that records more than 70,000 outpatient visits each year. The results reflect KFSH’s approach to heart failure as a long-term condition that is best managed continuously, with technology keeping specialist teams in contact with patients between visits. King Faisal Specialist Hospital and Research Centre was ranked first in the Middle East and Africa and 12th globally among the world’s top 250 academic medical centers for 2026, and was named the most valuable healthcare brand in Saudi Arabia and the Middle East for 2026 by Brand Finance. KFSH was also recognized by Newsweek among the world’s best hospitals, best smart hospitals, and best specialized hospitals for 2026. For more information, please contact Media Coverage at KFSH: mediacoverage@kfshrc.edu.sa A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/89c2fcf4-e51b-4a27-951c-7b5ed78bdc8a

Continue Reading →

Conavi Medical Announces New Grants of Stock Options

Financial by 0 comments

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has granted an aggregate of 1,600,000 stock options to purchase common shares of the Company to officers of the Company pursuant to the Company’s Omnibus Equity Incentive Plan (the “Plan”). The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the date of grant. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly instalments over the subsequent 36 months, subject to the terms of the Plan. The grant of these stock options remains subject to the approval of the TSX Venture Exchange. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/. Forward looking information This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact Mark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com

Continue Reading →
Detlef Schumann

Groundbreaking therapy for advanced heart failure: Repairon Strengthens Executive Leadership with Appointment of Detlef Schumann, Ph.D. as Chief Operating Officer

Financial by 0 comments

Biotech executive brings global leadership and operations experience to speed clinical development, expand operations, and carry out strategic growth plans.GÖTTINGEN, Germany and PROVIDENCE, R.I., Oct. 19, 2026 (GLOBE NEWSWIRE) — Repairon, a biotechnology company developing regenerative cardiac therapies, today announced the appointment of Detlef Schumann, Ph.D. as Chief Operating Officer. Schumann will report to CEO Lothar Germeroth, Ph.D. and oversee global operations and strategic growth initiatives. Dr. Schumann brings extensive executive leadership experience across biotechnology, pharmaceuticals, and medical devices, combining deep scientific and technical expertise in cell therapy, advanced therapy medicinal products (ATMPs), regenerative medicine, and medical devices with a strong track record in operational excellence, organizational development, GMP manufacturing, automation, strategic partnerships, and M&A. He has developed and implemented international growth strategies, with particular expertise in EMEA, Japan and Singapore. As CEO of TETEC Tissue Engineering Technologies AG, he established sustained growth through the restructuring and scaling of GMP-compliant ATMP manufacturing operations and highly specialized CDMO services. He served as Managing Director of CeGaT GmbH, Vice President for Technology Innovation at B. Braun Aesculap, and held senior research and business development positions at DSM Biomedical. Dr. Schumann holds a degree in pharmacy and a doctorate in regenerative medicine and pharmaceutical technology from the University of Regensburg, Germany. His academic research experience includes postdoctoral fellowships at MIT/Harvard and the National University of Singapore. Repairon’s CEO, Lothar Germeroth, remarked that “the addition of Detlef Schumann to our senior leadership team is crucial for the company’s forthcoming expansion. His experience and leadership will have a direct impact on scaling up production, executing pivotal clinical trials, increasing focus on Far East markets, and managing and growing our revenue-generating activities in Germany. Fueled by the positive clinical outcomes of our Phase I-II clinical study, as the first company to demonstrate the restoration of heart muscle in ischemic advanced heart failure patients, we look forward to developing Repairon’s BioVAT product. “Contributing to the clinical, regulatory, and commercial development of one of the most significant tissue engineering technologies in cardiovascular medicine is a fabulous opportunity and a significant responsibility,” said Detlef Schumann. “I look forward to applying all my skills, experience, and energy to build Repairon and develop BioVAT for the benefit of millions of advanced heart failure patients worldwide.”     High medical need in advanced heart failure: Approximately 5% of the global population suffers from chronic heart failure of any severity, and it remains one of the most common causes of death. In the US, heart failure represents the most common cause of hospitalization and mortality in the senior population, and over 6 million people are affected. As heart failure progresses to advanced stages, patients experience weakness with discomfort during all physical activities and at rest, sometimes even requiring constant bed rest. For these severely ill patients, the only treatment options currently available are mechanical pump devices or heart transplantation. About Repairon: Repairon GmbH is a German biotech company based in Göttingen, Germany, focused on developing regenerative cell therapies for cardiac medicine. The company was founded in 2014 based on research by Wolfram-Hubertus Zimmermann, MD and his team at the University Medical Center Goettingen, who have developed several tissue engineering technologies with proven applicability for organ repair and drug development. Repairon’s lead therapeutic candidate, the human engineered heart muscle patch, is currently being evaluated in the BioVAT-HF Phase 2 clinical trial as a biological ventricular assist tissue (BioVAT) for end-stage heart failure. Company contact:Dr. Lothar GermerothRepairon GmbH37079 Göttingen – GermanyEmail: germeroth@repairon.deUS contact:Frank AhmannRepairon USAProvidence, RI Email: f.ahmann@repairon.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/64985d27-8653-4e2b-a6b9-38b0d3a46954

Continue Reading →

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

Coronary/Structural Heart Regulatory by 0 comments

SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery. In May 2026, the Company and FDA met and reviewed our initial De Novo pre-submission package. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the product’s safety data, performance, or compatibility with general classes of agents. In August 2026, FDA confirmed and accepted the meeting minutes. In September 2026, the De Novo pre-submission was revised, incorporating the advice from FDA CDRH as detailed in the meeting minutes, re-submitted and has now been accepted by FDA. BioCardia expects FDA substantive review with written feedback, followed by a meeting with BioCardia to discuss approval via the De Novo pathway, this quarter. The extensive clinical data and safety profile from fifteen clinical trials including nearly five hundred patients presents an opportunity for FDA to ensure that follow-on catheters demonstrate a similar level of safety and clinical experience to obtain clearance. Marketing clearance of Helix by FDA has the potential to expand BioCardia’s opportunities to partner with developers of investigational cells, genes, and protein therapeutics requiring targeted delivery to the heart.  About the Helix Transendocardial Delivery Catheter The Helix transendocardial delivery catheter is an enabling platform for minimally invasive targeted delivery of therapeutic and diagnostic agents to the heart intramyocardially. It enables agents to be delivered precisely within the heart with superior retention over other therapeutic delivery modalities, and to many regions of the heart that other delivery methods cannot reach. The Helix includes a specialized small distal helical needle which engages the heart tissue from within the chamber of the heart and provides stability within the dynamic beating heart to safely enable agent delivery. About BioCardia BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. Forward Looking Statements  This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. MEDIA CONTACT:Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT:David McClung, Chief Financial Officerinvestors@biocardia.com (650) 226-0120

Continue Reading →
1 2 3 … 1,385